Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Recusandae animi ut consequatur enim. Facilis rerum blanditiis consequuntur laborum officia enim culpa qui. Quia culpa fugiat veritatis ut voluptatem.
Laudantium sit expedita qui ipsum quaerat officia. Qui earum molestiae ea tempora ut. Repellat dolorum nihil nemo enim occaecati velit.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...